Abstract
Objective: To compare the healthcare costs of patients with hypopituitarism with those of individuals from the general population.
Design: Aretrospective study of costs over 1 year. Estimates of direct and indirect health-related costs were calculated for patients from the general population using existing databases, and for patients with hypopituitarism using records of all patients eligible to participate on 31 December 1989 who could be traced, were willing to participate and had not been treated for acromegaly or Cushing’s disease.
Setting: The catchment area of the Endocrine Unit, Sahlgrenska Hospital, Gothenburg. The study was conducted from the societal perspective. Reference data were collected from official regional and national registries.
Patients: 199 patients with adult-onset hypopituitarism in whom replacement therapy was given to maintain the adrenal, thyroid and gonadal (but not the somatotropic) axes.
Main outcome measures and results: Direct and indirect costs incurred by patients with hypopituitarismwere higher than those incurred by individuals from the general population. The total direct costs per patient were Swedish Crowns (SEK)22 920 vs SEK12 080 (p < 0.003) in the general population, and the highest costs were related to inpatient care. Of the patients aged 16 to 64 years, 22% had drawn a disability pension versus the expected 11.3% (p < 0.003) in the general population, and the patients had a mean sick leave of 38.4 days vs 23.5 (p < 0.001). Total excess costs for all patients with hypopituitarism were SEK 35 768 per patient (p < 0.007).
Conclusions: Patients with hypopituitarism incur more health-related costs than individuals from the general population. They also take more sick leave days and are more likely to claim a disability pension than members of the general population. Further cost analyses are needed to determine whether improvements in diagnostic and surgical procedures, and hormone replacement therapy, can reduce the healthcare costs of patients with hypopituitarism.
Similar content being viewed by others
References
Sönksen PH. Replacement therapy in hypothalamo–pituitary insufficiency after childhood: management in the adult. Horm Res 1990; 33 Suppl. 4: 45–51
Hakkaart-van Roijen L, Beckers A, Stevenaert A, et al. The burden of illness of hypopituitary adults with growth hormone deficiency. Pharmacoeconomics 1998; 14: 395–403
Sanmarti A, Lucas A, Hawkins F, et al., Collaborative ODA (Observational GH Deficiency in Adults) Group. Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study): socio-economic impact and health status. Eur J Endocrinol 1999; 141 (5): 481–9
Jönsson B. Diabetes: the cost of illness and the cost of control. An estimate for Sweden 1978. Acta Med Scand Suppl 1983; 671: 19–27
Finkler SA. The distinction between cost and charges. Ann Intern Med 1982; 96 (1): 102–9
KoopmanschapMA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc SciMed 1992; 34 (9): 1005–10
Gerard K, Donaldson C, Maynard AK. The cost of diabetes. Diabetes Med 1989; 6 (2): 164–70
An official investigation: needs and resources in healthcare – an analysis [in Swedish]. Stockholm:Ministry of Health and Social Affairs, 1996
The National Social Insurance Board. Disability pensions: cost and number of reimbursed pensioners in December 1989 [in Swedish]. Stockholm: Riksförsäkringsverket
National Bureau of Statistics. Statistical yearbook of Sweden 1998. Stockholm: Official Statistics of Sweden, 1998
Lindgren B. The economic impact of illness. In: Abshagen U, Munnich FE, editors. Cost of illness and benefits of drug treatment. Munich: WZuckschwerdt Verlag, 1990: 12–20
Drummond M. Cost-of-illness studies: a major headache. Pharmacoeconomics 1992; 2 (1): 1–4
Thorner MO, Vance ML, Horvath E, et al. The anterior pituitary. In: Wilson JD, Foster DW, editors. Williams textbook of endocrinology. 8th ed. Philadelphia (PA): WB Saunders Company, 1992: 221–310
Rosén T, Bengtsson B-Å. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285–8
Markussis V, Beshyah SA, Fisher C, et al. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992; 340: 1188–92
Bülow B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 1997; 46: 75–81
Rosén T, Hansson T, Granhed H, et al. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol 1993; 129: 201–8
Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, et al. Increased fracture frequency in adult patients with hypopituitarism. Eur J Endocrinol 1997; 137: 240–5
Acknowledgements
Paul Verboom, MSc, is gratefully acknowledged for his support in completing the analyses. The authors are indebted to Pharmacia & Upjohn and the Swedish Medical Research Council (Grant 244115707) for economic support. This article was presented in part at the Annual Meeting of the Endocrine Society, Minneapolis, Minnesota, USA, in June 1997.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ehrnborg, C., Roijen, L.HV., Jonsson, B. et al. Cost of Illness in Adult Patients with Hypopituitarism. Pharmacoeconomics 17, 621–628 (2000). https://doi.org/10.2165/00019053-200017060-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200017060-00008